Articles with public access mandates - Morten Mau-SorensenLearn more
Not available anywhere: 2
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours
R Plummer, H Swaisland, K Leunen, CM van Herpen, G Jerusalem, ...
Cancer Chemother Pharmaco 76, 723-729, 2015
Mandates: Cancer Research UK, National Institute for Health Research, UK
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and renal impairment
C Rolfo, J de Vos-Geelen, N Isambert, LR Molife, JHM Schellens, ...
Clinical Pharmacokinetics 58, 1165-1174, 2019
Mandates: Cancer Research UK, National Institute for Health Research, UK
Available somewhere: 10
Enhanced detection of circulating tumor DNA by fragment size analysis
F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ...
Science translational medicine 10 (466), eaat4921, 2018
Mandates: US National Institutes of Health, Cancer Research UK, UK Engineering and …
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ...
The lancet oncology 20 (3), 383-393, 2019
Mandates: Cancer Research UK, National Institute for Health Research, UK
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
R Garzon, M Savona, R Baz, M Andreeff, N Gabrail, M Gutierrez, L Savoie, ...
Blood, The Journal of the American Society of Hematology 129 (24), 3165-3174, 2017
Mandates: US National Institutes of Health
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ...
Cancer discovery 10 (2), 198-213, 2020
Mandates: US National Science Foundation, US National Institutes of Health, V …
A phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma
AB Lassman, PY Wen, MJ van den Bent, SR Plotkin, AME Walenkamp, ...
Clinical Cancer Research 28 (3), 452-460, 2022
Mandates: US National Institutes of Health
Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies
L Dirix, H Swaisland, HMW Verheul, S Rottey, K Leunen, G Jerusalem, ...
Clinical Therapeutics 38 (10), 2286-2299, 2016
Mandates: Cancer Research UK
Serum IL6 as a prognostic biomarker and IL6R as a therapeutic target in biliary tract cancers
D Høgdall, CJ O'Rourke, C Dehlendorff, OF Larsen, LH Jensen, ...
Clinical cancer research 26 (21), 5655-5667, 2020
Mandates: US National Institutes of Health, Danish Council for Independent Research …
Spectrum analyzer-based phase measurement for near-field EMI scanning
S Marathe, Z Chen, K Ghosh, H Kajbaf, S Frei, M Sørensen, ...
IEEE Transactions on Electromagnetic Compatibility 62 (3), 848-858, 2019
Mandates: US National Science Foundation
Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy
A Borch, AM Bjerregaard, V Araujo Barbosa de Lima, O Østrup, CW Yde, ...
Frontiers in genetics 14, 1058605, 2023
Mandates: European Commission
DNA methylation markers for sensitive detection of circulating tumor DNA in patients with gastroesophageal cancers
N Ogaard, CR Iden, S Ostrup Jensen, SM Mustafa, E Aagard, JB Bramsen, ...
medRxiv, 2024.03. 04.24303699, 2024
Mandates: Cancer Research UK
Publication and funding information is determined automatically by a computer program